Drug intelligence / Profile preview

EX1000

Development stage: Phase 2
Lead developer: Exscientia
Modality: Small Molecules
Administration: Subcutaneous

Overview

EX1000 is an investigational drug referenced in clinical trials as a comparator to biphasic human insulin 100 IU/mL for the management of blood glucose in patients with type 2 diabetes. The specific molecular identity, mechanism of action, and detailed pharmacological profile of EX1000 are not publicly disclosed in available sources. It is distinct from other similarly named products (such as exenatide or medical devices labeled "EX-1000") and appears to be a unique experimental formulation evaluated for glycemic control in diabetes[2][9].

Beyond the preview

Go deeper on EX1000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EX1000.

Explore the full profile